Determinants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancer

被引：0
|
作者：
Frederik A. Verburg
Uwe Mäder
Markus Luster
Heribert Hänscheid
Christoph Reiners
机构：
[1] University of Würzburg,Department of Nuclear Medicine
[2] University of Würzburg,Comprehensive Cancer Center Mainfranken
[3] RWTH University Hospital Aachen,Department of Nuclear Medicine
[4] University Hospital Giessen and Marburg,Department of Nuclear Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2015年 / 42卷
关键词：
Differentiated thyroid carcinoma; Complete remission; I Therapy; Paediatric cancer; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1390 / 1398
页数：8
相关论文
共 50 条
  • [31] The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma
    Thies, Elena-Daphne
    Tanase, Karina
    Maeder, Uwe
    Luster, Markus
    Buck, Andreas K.
    Haenscheid, Heribert
    Reiners, Christoph
    Verburg, Frederik A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (12) : 2281 - 2290
  • [32] Required therapeutic dose of 131I for thyroid ablation after surgery for differentiated thyroid carcinoma
    Yaneva, M.
    Botushanova, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S399 - S399
  • [33] The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma
    Elena-Daphne Thies
    Karina Tanase
    Uwe Maeder
    Markus Luster
    Andreas K. Buck
    Heribert Hänscheid
    Christoph Reiners
    Frederik A. Verburg
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 2281 - 2290
  • [34] The combination of 18F-FDG PET, 201Tl scintigraphy, and 131I scintigraphy improves the rate of detecting differentiated thyroid cancer undergoing 131I therapy after total thyroidectomy.
    Kato, K
    Iwano, S
    Tadokoro, M
    Ikeda, M
    Kobayashi, H
    Nishino, M
    Abe, S
    Nakayama, Y
    Nakano, S
    Ishigaki, T
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 327P - 327P
  • [35] Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy
    Gao, Y.
    Tang, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S540 - S540
  • [36] The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy
    van Dijk, D.
    Plukker, J. T. M.
    van der Horst-Schrivers, A. N. A.
    Jansen, L.
    Brouwers, A. H.
    Muller-Kobold, A.
    Sluiter, W. J.
    Links, T. P.
    CLINICAL ENDOCRINOLOGY, 2011, 74 (01) : 104 - 110
  • [37] Prognostic Value of Thyroglobulin Levels and Therapeutic 131I Whole-Body Scan after Initial 131I Ablation of Differentiated Thyroid Cancer
    Luo, Q.
    Yu, Y.
    Lu, H.
    Zhu, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S241 - S241
  • [38] Preablation Stimulated Thyroglobulin/TSH Ratio As a Predictor of Successful I131remnant Ablation in Patients with Differentiated Thyroid Cancer Following Total Thyroidectomy
    Hussain, Syed Zubair
    Zaman, Maseeh Uz
    Malik, Sarwar
    Ram, Nanik
    Asghar, Ali
    Rabbani, Unaib
    Aftab, Nida
    Islam, Najmul
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [39] Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
    Yin, Xue
    Lu, Chao
    Sun, Danyang
    Ji, Yanhui
    Wang, Yan
    Zheng, Hongyuan
    Ma, Ziyu
    Jia, Qiang
    Tan, Jian
    Zheng, Wei
    ENDOCRINE, 2024, 84 (03) : 1064 - 1071
  • [40] TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer
    Ju, Nianting
    Hou, Liying
    Song, Hongjun
    Qiu, Zhongling
    Wang, Yang
    Sun, Zhenkui
    Luo, Quanyong
    Shen, Chentian
    EUROPEAN THYROID JOURNAL, 2023, 12 (04)
12345